Bristol and Janssen detailed the now under way Phase III program for Factor XIa inhibitor milvexian and BMS shared data at ACC to help prescribers get comfortable with Camzyos, launched last year.

From synthetic data to real-world data, from patient engagement to patient stratification, from combination trials to master protocols and from fully decentralized through hybrid to onsite trials, the world of clinical development is undergoing major changes. Fifty executives share their predictions around clinical trial trends for the year ahead.

The Fresenius group spoke at length about its core Fresenius Kabi business during the company’s year-end financial call, not least its under pressure IV drugs in the US.

Dr Reddy’s has struck a deal to pay at least $90m for the US prescription generics portfolio of Mayne Pharma. The transaction covers products including Mayne’s recently-launched rival to NuvaRing.